Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-center, Phase II Trial of Cetuximab+Zimberelimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT06107114 is registered in ClinicalTrials.gov with Xuekui Liu as lead sponsor.

NCT NCT06107114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06107114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-center, Phase II Trial of Cetuximab+Zimberelimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Xuekui Liu
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2023
Completion date
December 1, 2024
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hend and neck squamous cell carcinoma locally advanced operable